Moleculin Biotech (NASDAQ:MBRX) Announces Quarterly Earnings Results

Moleculin Biotech (NASDAQ:MBRX) released its earnings results on Thursday. The company reported ($1.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.55) by $0.15, FiscalAI reports.

Moleculin Biotech Stock Performance

Moleculin Biotech stock traded up $0.05 during mid-day trading on Thursday, reaching $0.57. The company’s stock had a trading volume of 1,322,819 shares, compared to its average volume of 567,823. The firm’s fifty day moving average price is $2.06 and its two-hundred day moving average price is $2.51. Moleculin Biotech has a 12-month low of $0.16 and a 12-month high of $17.23. The company has a market capitalization of $4.06 million, a P/E ratio of -0.03 and a beta of 1.83.

Hedge Funds Weigh In On Moleculin Biotech

An institutional investor recently bought a new stake in Moleculin Biotech stock. Jane Street Group LLC purchased a new stake in Moleculin Biotech, Inc. (NASDAQ:MBRX) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned approximately 1.11% of Moleculin Biotech as of its most recent filing with the Securities & Exchange Commission. 15.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently weighed in on MBRX shares. Wall Street Zen downgraded Moleculin Biotech from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Weiss Ratings restated a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Friday, July 17th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $22.00.

About Moleculin Biotech

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.